Search results for "CERAMIDE"

showing 10 items of 94 documents

Oxidative stress biomarkers in Fabry disease: is there a room for them?

2020

Abstract Background Fabry disease (FD) is an X-linked lysosomal storage disorder, caused by deficient activity of the alpha-galactosidase A enzyme leading to progressive and multisystemic accumulation of globotriaosylceramide. Recent data point toward oxidative stress signalling which could play an important role in both pathophysiology and disease progression. Methods We have examined oxidative stress biomarkers [Advanced Oxidation Protein Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), thiolic groups] in blood samples from 60 patients and 77 healthy controls. Results AOPP levels were higher in patients than in controls (p < 0.00001) and patients presented decreased levels of…

0301 basic medicinemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentGlobotriaosylceramideOxidative phosphorylationDiseasemedicine.disease_cause03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelysoGb3Internal medicinemedicineHumansFabry diseaseOriginal Communicationbusiness.industryBiomarkermedicine.diseaseFabry diseasePathophysiologyOxidative Stress030104 developmental biologyEndocrinologyNeurologychemistryAdvanced oxidation protein productsalpha-GalactosidaseMutationNeurology (clinical)businessBiomarkers030217 neurology & neurosurgeryOxidative stressJournal of Neurology
researchProduct

Short Term Palmitate Supply Impairs Intestinal Insulin Signaling via Ceramide Production

2016

International audience; The worldwide prevalence of metabolic diseases is increasing, and there are global recommendations to limit consumption of certain nutrients, especially saturated lipids. Insulin resistance, a common trait occurring in obesity and type 2 diabetes, is associated with intestinal lipoprotein overproduction. However, the mechanisms by which the intestine develops insulin resistance in response to lipid overload remain unknown. Here, we show that insulin inhibits triglyceride secretion and intestinal microsomal triglyceride transfer protein expression in vivo in healthy mice force-fed monounsaturated fatty acid-rich olive oil but not in mice force-fed saturated fatty acid…

0301 basic medicinemedicine.medical_specialtyCeramidemedicine.medical_treatmentPalmitic Acid[SDV.BC]Life Sciences [q-bio]/Cellular BiologyPalm OilCeramidesBiochemistryPalmitic acidMice03 medical and health scienceschemistry.chemical_compoundInsulin resistance[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyInternal medicinemedicineAnimalsHumansInsulinPlant OilsIntestinal MucosaPhosphorylationMolecular BiologyComputingMilieux_MISCELLANEOUS2. Zero hungerbiologyTriglycerideInsulinCell BiologyLipid signalingmedicine.diseaseLipids3. Good healthInsulin receptorEnterocytes030104 developmental biologyEndocrinologychemistrySaturated fatty acidbiology.proteinCaco-2 CellsProto-Oncogene Proteins c-akt[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologySignal TransductionJournal of Biological Chemistry
researchProduct

Antidepressive-like Behavior-Related Metabolomic Signatures of Sigma-1 Receptor Knockout Mice

2022

Sigma-1 receptor (Sig1R) has been proposed as a therapeutic target for neurological, neu-rodegenerative, and psychiatric disorders, including depression and anxiety. Identifying metabolites that are affected by Sig1R absence and cross-referencing them with specific mood-related behaviors would be helpful for the development of new therapies for Sig1R-associated disorders. Here, we examined metabolic profiles in the blood and brains of male CD-1 background Sig1R knockout (KO) mice in adulthood and old age and correlated them with the assessment of depression-and anxiety-related behaviors. The most pronounced changes in the metabolic profile were observed in the plasma of adult Sig1R KO mice.…

:PHARMACY::Biopharmacy [Research Subject Categories]sigma-1 receptorMedicine (miscellaneous)metabolomic signaturesceramidedespair behaviorGeneral Biochemistry Genetics and Molecular Biologyserotonin
researchProduct

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

Proeryptotic Activity of 4-Hydroxynonenal: A New Potential Physiopathological Role for Lipid Peroxidation Products

2020

Background: Eryptosis is a physiological, apoptosis-like death of injured erythrocytes crucial to prevent premature haemolysis and the pathological sequalae generated by cell-free haemoglobin. When dysregulated, the process is associated to several inflammatory-based pathologies. 4-Hydroxy-trans-2-nonenal (HNE) is an endogenous signalling molecule at physiological levels and, at higher concentrations, is involved in the pathogenesis of several inflammatory-based diseases. This work evaluated whether HNE could induce eryptosis in human erythrocytes. Methods: Measurements of phosphatidylserine, cell volume, intracellular oxidants, Ca++, glutathione, ICAM-1, and ceramide were assessed by flow …

Adult0301 basic medicineCeramideErythrocyteslcsh:QR1-502PhosphatidylserinesBiochemistryArticleRBClcsh:Microbiology4-HydroxynonenalLipid peroxidationprostaglandins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineeryptosisCell AdhesionHuman Umbilical Vein Endothelial CellsHumansMolecular BiologyCells CulturedCaspaseAldehydesbiologyGlutathionePhosphatidylserineMiddle AgedIntercellular Adhesion Molecule-1Haemolysislipid peroxidation productsGlutathione4-hydroxynonenalCell biology030104 developmental biologychemistryinflammation030220 oncology & carcinogenesisbiology.proteinCalciumLipid PeroxidationIntracellularBiomolecules
researchProduct

Skin-PAMPA: a new method for fast prediction of skin penetration.

2011

The goal of this study was to develop a quick, reliable, and cost-effective permeability model for predicting transdermal penetration of compounds. The Parallel Artificial Membrane Permeability Assay (PAMPA) was chosen for this purpose, as it already has been successfully used for estimating passive gastrointestinal absorption and blood-brain barrier permeability. To match the permeability of the rate-limiting barrier in human skin, synthetic certramides, which are analogs of the ceramides present in the stratum corneum, were selected for the skin-PAMPA model. The final skin-PAMPA membrane lipid mixture (certramide, free fatty acid, and cholesterol) was selected and optimized based on data …

AdultCell Membrane PermeabilityDatabases FactualTransdermal penetrationSkin AbsorptionSynthetic membranePharmaceutical ScienceHuman skinAdministration CutaneousCeramidesModels BiologicalMembrane LipidsDrug DiscoveryStratum corneummedicineHumansSkinChromatographyintegumentary systemChemistryReproducibility of ResultsMembranes ArtificialMiddle AgedLipid MetabolismPermeability (earth sciences)medicine.anatomical_structureMembraneSkin penetrationBarrier permeabilityEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Involvement of caspase-3 and GD3 ganglioside in ceramide-induced apoptosis in Farber disease.

2000

Farber's disease (FD) is a rare genetic disorder caused by ceramidase deficiency, which results in ceramide accumulation in lung, liver, colon, skeletal muscle, cartilage, and bone. Although this disease has been symptomatically characterized, little is known about its molecular pathogenetic process. Because recent studies reported that ceramide accumulation induces GD3 ganglioside formation and apoptosis, we investigated, in tissue obtained via colonoscopy from seriously involved patients, the possible involvement of ceramide in FD colonocyte destruction. Histochemical and TUNEL analyses of paraffin-embedded sections revealed that 45 ± 4.3% of FD colonocytes showed morphological signs of …

AdultCeramidePathologymedicine.medical_specialtyHistologyColonCaspase 3ApoptosisCeramideschemistry.chemical_compoundGangliosidesmedicineGD3 gangliosideHumansIntestinal MucosaCaspaseFarber diseaseFarber diseaseTUNEL assaybiologyCaspase 3ApoptosiCell Biologymedicine.diseaseCeramidaseCaspaseK18EpitheliumActive caspase-3Lysosomal Storage Diseasesmedicine.anatomical_structurechemistryApoptosisCaspasesCancer researchbiology.proteinAnatomyActive caspase-3; Apoptosis; Caspases; Farber disease; GD3 ganglioside; K18; Anatomy; Cell BiologyThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
researchProduct

Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry

2011

Morbus Fabry is a hereditary metabolic disorder with low prevalence and late clinical manifestation. A defect in the α-galactosidase gene leads to lysosomal accumulation of the glycolipid globotriaosylceramide (Gb3). Gb3 may be used for monitoring of enzyme replacement therapy (ERT), but diagnostic sensitivity is limited. Recently, globotriaosylsphingosine (lysoGb3) was introduced as a promising new marker with significantly better sensitivity. For Fabry diagnosis, clinical studies and possible therapy monitoring, we established a fast and reliable LC-MS/MS assay for quantification of lysoGb3 in human plasma. Protein precipitation and glycolipid extraction from EDTA plasma was performed usi…

AdultMaleAnalyteMolecular Sequence DataClinical BiochemistryGlobotriaosylceramideChemical FractionationTandem mass spectrometryBiochemistryHigh-performance liquid chromatographyAnalytical Chemistrychemistry.chemical_compoundTandem Mass SpectrometrymedicineHumansProtein precipitationDerivatizationChromatography High Pressure LiquidSphingolipidsChromatographyElutionTrihexosylceramidesReproducibility of ResultsCell BiologyGeneral Medicinemedicine.diseaseFabry diseaseCarbohydrate SequencechemistryCase-Control StudiesLinear ModelsFabry DiseaseFemaleGlycolipidsBiomarkersJournal of Chromatography B
researchProduct

De novo mutation in a male patient with Fabry disease: a case report

2014

Abstract Background Fabry disease is an X-linked inherited metabolic condition where the deficit of the α-galactosidase A enzyme, encoded by the GLA gene, leads to glycosphingolipid storage, mainly globotriaosylceramide. To date, more than 600 mutations have been identified in human GLA gene that are responsible for FD, including missense and nonsense mutations, small and large deletions. Such mutations are usually inherited, and cases of de novo onset occur rarely. Case presentation In this article we report an interesting case of a 44-year-old male patient suffering from a severe form of Fabry disease, with negative family history. The patient showed signs such as cornea verticillata, ang…

AdultMaleProtein Foldingα-galactosidase ADe novo mutationNonsense mutationD165H mutationGlobotriaosylceramideMutation MissenseCase ReportBiologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundGermline mutationmedicineMissense mutationHumansPoint MutationThrombophiliaEnzyme Replacement TherapyAmino Acid SequenceChildGLA geneConserved SequenceGerm-Line MutationMedicine(all)GeneticsMutationFabry diseaseSequence Homology Amino AcidBiochemistry Genetics and Molecular Biology(all)Point mutationGeneral MedicineEnzyme replacement therapymedicine.diseaseFabry diseasePedigreeStrokechemistryAmino Acid Substitutionalpha-GalactosidaseKidney Failure ChronicFemaleSymptom AssessmentSequence AlignmentBMC Research Notes
researchProduct

Extreme duration exercise affects old and younger men differently.

2022

Aim & Methods: Extreme endurance exercise provides a valuable research model for understanding the adaptive metabolic response of older and younger individuals to intense physical activity. Here, we compare a wide range of metabolic and physiologic parameters in two cohorts of seven trained men, age 30 ± 5 years or age 65 ± 6 years, before and after the participants travelled ≈3000 km by bicycle over 15 days. Results: Over the 15-day exercise intervention, participants lost 2–3 kg fat mass with no significant change in body weight. V̇O2max did not change in younger cyclists, but decreased (p = 0.06) in the older cohort. The resting plasma FFA concentration decreased markedly in both gro…

AdultMalecyclingPhysiologyRestendurance exerciseMASSINTRAMYOCELLULAR CERAMIDE ACCUMULATIONH2O2 EMISSIONenergy metabolismHumansCONTROLLED TOURMuscle SkeletalExerciseTriglyceridesAgedaerobic fitnessMORTALITYagingBody WeightENERGY-EXPENDITUREfat oxidationMiddle AgedINSULINPHYSICAL-ACTIVITYMAXIMAL FAT OXIDATIONPhysical EnduranceSKELETAL-MUSCLEmuscle biopsySettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieActa physiologica (Oxford, England)
researchProduct